Aurobindo Pharma Share Price: Q3 Results Out! Profit **23%** Chadh Gaya, Par Revenue Thoda Gira!

OTHER
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Aurobindo Pharma Share Price: Q3 Results Out! Profit **23%** Chadh Gaya, Par Revenue Thoda Gira!
Overview

Aurobindo Pharma ne apne Q3 FY26 ke results announce kar diye hain, aur bhai, standalone profit toh ekdum zordaar **23.3%** badh gaya hai! Lekin haan, standalone revenue mein **5.4%** ki girawat dekhne ko mili hai.

Aakhir ye hua kaise? Numbers dekhte hain!

Standalone basis par dekha jaaye toh December 2025 ko khatam hue quarter mein company ka Profit After Tax (PAT) ₹5,820.7 million tak pahunch gaya, jo pichhle saal ke comparison mein 23.3% zyada hai. Par wahi, revenue ₹27,263.8 million par aaya hai, jo 5.4% kam hai. Company ka kehna hai ki iska EPS ₹10.02 ho gaya hai, jo pehle ₹8.13 tha.

Ab consolidated figures ki baat karein toh yahaan picture thodi better hai. Revenue 8.9% badhkar ₹86,045.1 million ho gaya aur consolidated PAT mein bhi 7.6% ka jump aaya hai, jo ₹9,098.0 million hai. 9 mahino ki baat karein toh consolidated revenue 7.1% badhi hai, par PAT lagbhag flat, sirf 0.05% badhi hai.

Ek 'exceptional item' bhi tha, jiski wajah se standalone results mein ₹173.8 million aur consolidated mein ₹653.3 million ka impact pada hai. Yeh naye Labour Codes ki wajah se gratuity aur leave liabilities badhne ke karan hua hai.

Toh iska matlab kya?

Standalone profit mein itna bada jump, revenue kam hone ke bawajood, iska matlab hai ki company ne cost cutting acchi ki hai ya phir high-margin products ka mix behtar raha hoga. Lekin 9 mahino mein consolidated PAT ka flat rehna thoda sochne wala point hai.

Aage kya plan hai?

Company ne ek mast move liya hai! Board ne ₹66 crore approve kiye hain Garuda Renewables mein 26% stake kharidne ke liye. Yeh renewable energy mein investment hai jisse future mein bijli ka kharcha kam hoga aur ESG profile bhi sudhrega. Is deal ke poora hone mein lagbhag 6 mahine lag sakte hain. Iske alawa, company apni subsidiaries ko merge bhi kar rahi hai taaki operations streamline ho aur kharche kam hon.

Ek naye Director, Dr.(Mrs.) Punita Kumar Sinha, bhi jud gayi hain jinke paas capital markets aur governance ka accha experience hai. Company basically ek hi segment mein kaam karti hai: Pharmaceuticals.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.